How are guidelines diVerent from systematic reviews or expert consensus? Systematic reviews of interventions entail ongoing searches of the literature pertinent to the area of interest following a methodical approach (comprehensive electronic searches, hand searching of bibliographies and journals, etc). The available information is then classified according to pre-determined methods to evaluate the degree of scientific validity, with controlled clinical trials as the benchmark. Finally, if certain assumptions are met, findings from various sources may be pooledsynthesised quantitatively-(meta-analysis). The Cochrane Collaboration is a worldwide organisation with a mandate to produce systematic reviews of health interventions, 22 but it does not produce guidelines. Consensus methods on the other hand are based on strategies that create structured environments in which experts provide levels of agreement on unresolved, and often controversial subjects. Guidelines are statements about practice developed following an evidence-based approach, expert recommendations, or a combination of both. If the evidence for a particular clinical scenario is solid-that is, several randomised clinical trials with comparable results-excellent CPGs can be developed that should readily be accepted by most. In this situation however, practice variation may be more limited and eventually, many physicians may adopt, albeit gradually, the new evidence into their practice. When the evidence for particular interventions is absent or weak, variation can understandably occur. An example of such scenarios is illustrated by the early use of second line drugs in patients with rheumatoid arthritis where it is well recognised that many treatments are more eVective than placebo, 23 and that early administration produces a better response. 24 25 We found in our utilisation studies that second line therapy was given early and with the same frequency by both communitybased and academic rheumatologists in our health region. 12 26 On the other hand, significant variation was seen in the use of particular second line drugs, possibly reflecting the lack of evidence to strongly support one drug over the others. 23 Financial advantages and reimbursement incentives may result in inappropriate physician practices. 27 Economic profit may increase the utilisation of some interventions with no clear patient benefit. Although we believe that most physicians are decent human beings who care for the well being of their patients, we also recognise that economic incentives have important eVects on human behaviour. Inappropriate practice can therefore be expected if personal financial gains are substantial, in particular if there are no important harms to patients (for example, over utilisation of innocuous diagnostic tests). Yet, it is unclear how guidelines can change this pattern. If the motivation behind particular practices is economic, physicians may not modify their behaviour after a set of recommendations has been introduced. If the incentive is financial, the most eVective disincentive will also be financial, well beyond the scope of CPGs for physicians.
Can guidelines be useful? In our view they could be, if developed under certain guidelines! Systematic reviews of scientific evaluations of clinical guidelines have shown controversial results.
2 28 29 Grimshaw reported that CPGs could improve both the process of care and patient outcomes, but with wide variation in their eVect size.
2 On the other hand, recent reviews found no evidence that CPGs produced significant benefits in clinical outcomes. 28 29 In some instances nevertheless, the implementation of guidelines may be driven by economic considerations in contrast with beneficial patient outcomes. What attributes make CPGs worth the eVort?
Issue to be tackled
To have a significant impact, the condition for which guidelines are developed should be prevalent or costly, and inappropriately managed, including either a wide use of ineVective or harmful interventions, or practice variation resulting in diVering outcomes or costs.
Clear evidence
The ultimate goal of clinicians is to improve patient outcomes, and CPGs developed solely on the basis of financial considerations should not be accepted by the medical community. Clear evidence of eYcacy must be available before recommendations can be endorsed. 30 This evidence should be based in most instances on the results of randomised clinical trials. If economic aspects are the major driver for guideline implementation, it should be clear at the very least that there will not be a deleterious eVect on patient outcomes. Yet, even in the presence of solid evidence, the dissemination of new medical knowledge is a slow process. Antman 31 showed that interventions that could have saved lives were not adopted by experts in their recommendations until 10 years after the benefits had been clearly shown. How CPGs could improve this slow process is not clear. Given that experts seem to be as slow as practitioners in accepting new evidence, adding a new layer of scrutiny and evaluation with panels and task forces could possibly delay the process even more. The potential causes for this resistance to adopt new evidence are beyond the scope of our commentary. However, if evidence-based results are met with resistance, then merely opinions, even if from experts, can be expected to elicit more controversy. In our view, CPGs developed by expert panels in the absence of clear scientific evidence should be subjected to the same degree of scrutiny as any other intervention, and be tested in clinical settings before their wide implementation and adoption.
Scope
Parsimony is the key. Evidence is often clear for specific issues but insuYcient to tackle the whole picture. Guidelines could be developed recommending the best dose and administration route to begin treatment of rheumatoid patients with methotrexate. It is unlikely nevertheless that evidence-based guidelines could be established for the treatment of rheumatoid arthritis in general. This is too broad a scope, including interventions as dissimilar as diagnostic tests, drugs, surgery and rehabilitation, and patients with varying degrees of severity and disease duration. The Agency for Health Care Policy and Research (AHCPR) from the US Department of Health spent millions in the past decade to develop CPGs. Among others, they produced "Clinical Practice Guidelines for the Management of Acute Low Back Pain". 32 The scope of these guidelines includes "strategies for the assessment and treatment of acute low back problems in adults" by primary care physicians. The review of the literature was exhaustive, categorised into levels of evidence for recommendations. The document produced by AHCPR is an excellent systematic review on the current knowledge for the treatment of low back pain. It also includes guidelines for every aspect of care, from physical examination to referrals to surgeons presented, unfortunately, as complex graphical algorithms transporting patients across various decision nodes. The guidelines have been broadly distributed and published in North America. We were particularly interested in their recommendations on the initial use of lumbar radiographs in patients with low back pain, based on the recognition that they are seldom useful, and should only be considered if tumour, fracture or infection are suspected. The panel proposed a series of "red flags" or markers that could possibly identify patients with these disorders. "Red flags" included age, corticosteroid use, previous cancer, etc. We applied these criteria to over 960 consecutive patients with acute low back pain seen in primary care clinics. 33 Lumbar radiographs had been requested in 13% of the patients; if physicians had followed the AHCPR guidelines, use would have increased to 44%! These findings point to the need to evaluate CPGs in clinical settings before their wide dissemination, particularly if developed by consensus in the absence of clear data. In our view, the systematic review conducted by the AHCPR low back pain panel is scientific, comprehensive, and serves the medical community well. The guidelines however are too broad in their scope. An alternative approach would have been to identify two or three areas where inappropriate practice can be shown, where the evidence for an intervention is robust, the target patient population can be recognised, and complex algorithms are not required; for instance, prolonged bed rest is harmful for most patients with back pain, more costly than encouraging patients to maintain their level of activity, and is still widely recommended by some physicians. Unfortunately, much of the physician resistance to CPGs relates to the publication of bad guidelines, or recommendations with such a wide scope that they cannot be specifically applied to individual patients.
Physician targets
CPGs are often targeted at primary care physicians because it is clearly diYcult to keep abreast of new knowledge for all the conditions seen in primary care, and it is perceived that simple rules may facilitate care. Many guidelines, such as those produced by the American College of Rheumatology, target specialists. Of more interest to us is not the "type of physician" but the "type of human being" who could benefit from guidelines. Rogers has shown that the diVusion of innovations follows striking sinusoidal patterns. 34 People can be categorised according to their enthusiasm in adopting new technologies as: (a) innovators (venturesome); (b) early adopters (respectable); (c) early majority (deliberate); (d) late majority (sceptical); and (e) laggards (traditional). These categories apply to fields as diVerent as the use of herbicides by farmers, clothing fashions, and yes, medical practice. Socioeconomic status, personality, and communication behaviour relate to the various "adopter" categories. The challenge is to be able to modify inappropriate behaviour through diffusion of interventions (guidelines or other) in people with varying behaviours. "Late majority" and "laggards" may benefit from evidence gathered locally or incentives to change traditional practice patterns. "Innovators" and "early adopters" may need some restraint before embracing new technologies with unconfirmed benefits.
Development strategies
Guidelines have higher rates of success when developed internally (in contrast with nationally or internationally), with input from potential users, and involving opinion leaders respected by their peers. 35 Guidelines developed by a single national organisation (for example, American College of Rheumatology) cannot possibly consider the implications of varying patient populations, socioeconomic factors, and health costs for communities across the world.
Many of the diseases treated by rheumatologists vary in prevalence or prognosis across ethnic populations. Many procedures taken for granted in North America are not accessible for most patients in developing countries. Relative costs of health interventions also vary across countries as shown for everyday treatments such as non-steroidal anti-inflammatory drugs. 36 Local groups may not be able to undertake systematic reviews and CPG developments that are costly and time consuming. An alternative may be for local groups to select guidelines produced by national or international agencies and tailor them according to their needs, emphasising their involvement in the implementation phases.
Dissemination strategies
Specific educational interventions and continuing medical education have higher chances of success. Publication in journals have below average probability of being eVective. Yet, most CPGs are just published in journals, and seldom formally implemented. Identifying those physicians who may benefit from specific interventions and being selective in their implementation (that is, "laggards" versus "innovators") may be more eVective than a universal approach such as guideline diVusion in medical journals. More research is needed to evaluate physician behavioural changes with diVerent dissemination strategies, including the eVect of individual characteristics and beliefs on the success or failure of specific interventions.
Clinical practice guidelines should be considered as one more tool in the challenge to improve patient care. Are guidelines the solution for every medical dilemma? Evidently not. Some policy makers embrace CPGs as the solution to all problems. Unfortunately, most diYcult questions in clinical medicine remain diYcult because there is no clear answer. The "art of medicine" still plays an important part in everyday practice, but its focus is evolving. The "art of medicine" is not about applying anecdotal experiences to the solution of clinical problems, it is about critically appraising the evidence in front of us and linking it to our focus of interest, the individual patient.
